Prognostic and predictive role of soluble programmed death ligand-1 in head and neck cancer

Molga-Magusiak, Maria; Rzepakowska, Anna; Žůrek, Michal; Kotuła, Iwona; Demkow, Urszula; Niemczyk, Kazimierz

doi:10.1016/j.bjorl.2023.02.005

Cited by 5 publications

(5 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We discovered that patients aged between 35 and 45 years had significantly higher levels of sPD-L1 than those aged between 46 and 75 years. This interesting finding aligns with the research of Molga-Magusiak et al, who also found higher sPD-L1 levels in younger HNSCC patients [ 45 ]. However, the reasons for this correlation are still unknown.…”

Section: Discussionsupporting

confidence: 92%

“…In particular, the study by Zhang et al revealed that high sPD-L1 levels were linked to advanced disease stages, lymph node metastasis, and worse survival outcomes in HNSCC patients [ 47 ]. Similarly, a study by Molga-Magusiak et al reported that sPD-L1 levels were higher in HNSCC patients with advanced disease stages and lymph node metastasis [ 45 ].…”

Section: Discussionmentioning

confidence: 99%

“…Mean ± SD 55. 45 and percentage of patients considered for evaluating their response following induction chemotherapy, concurrent chemoradiotherapy, and completion of all therapy. Additionally, the table displays the number and percentage of patients who achieved a complete response (CR), partial response (PR), stable disease, or progressive disease (PD) during each phase of treatment.…”

Section: Range 35-75mentioning

confidence: 99%

See 2 more Smart Citations

Soluble Programmed Death-Ligand 1 (sPD-L1) as a Promising Marker for Head and Neck Squamous Cell Carcinoma: Correlations With Clinical and Demographic Characteristics

Alrehaili,

Gharib,

Almalki

et al. 2023

Cureus

View full text Add to dashboard Cite

Background and objective Head and neck squamous cell carcinoma (HNSCC) is a prevalent cancer type that affects the mucosal lining of the upper aerodigestive tract. Soluble programmed death-ligand 1 (sPD-L1) is a significant factor in hindering T cells' function, which prevents cancer cells from being detected by the immune system. This means that sPD-L1 is an essential component in the immune evasion of cancer. This study aimed to explore the potential of sPD-L1 as a prognostic biomarker for patients with HNSCC undergoing concurrent chemotherapy and radiation therapy. Methodology The study included 106 patients with locally advanced HNSCC who received three courses of induction chemotherapy followed by concurrent chemoradiation and 60 healthy subjects as controls. sPD-L1 levels were measured using an enzyme-linked immunosorbent assay (ELISA) kit, and the cutoff value was determined based on receiver operating characteristic (ROC) curve analysis. Results The results showed that sPD-L1 levels were significantly higher in HNSCC patients compared to healthy controls, with a cutoff value of 31.51 pg/mL. Higher sPD-L1 levels were associated with poorer overall survival rates. Conclusions These findings suggest that sPD-L1 may serve as a valuable prognostic biomarker for HNSCC patients undergoing concurrent chemotherapy and radiation therapy. The study highlights the importance of exploring new biomarkers and therapeutic strategies for HNSCC to improve patient outcomes and reduce morbidity and mortality rates associated with this disease.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Discussionmentioning

confidence: 99%

Section: Range 35-75mentioning

confidence: 99%

See 1 more Smart Citation

Soluble Programmed Death-Ligand 1 (sPD-L1) as a Promising Marker for Head and Neck Squamous Cell Carcinoma: Correlations With Clinical and Demographic Characteristics

Alrehaili,

Gharib,

Almalki

et al. 2023

Cureus

View full text Add to dashboard Cite

show abstract

“…Since high levels of sPD-L1 are correlated with poor prognosis in several types of carcinomas, [15][16][17][18] our study is the first to investigate the predictive value of sPD-L1 and sPD-L2 as PD-1 inhibitors in RMHNSCC. Contrary to tissue expression, high levels of sPD-L1 or sPD-L2 were associated with short OS with nivolumab.…”

Section: Discussionmentioning

confidence: 98%

Combined approach for predicting the efficacy of nivolumab in head and neck carcinoma by tissue and soluble expressions of PD‐L1 and PD‐L2

Sato,

Komatsuda,

Inoue

et al. 2024

Head & Neck

View full text Add to dashboard Cite

BackgroundPredictive biomarkers for nivolumab in recurrent or metastatic head and neck squamous cell carcinoma (RMHNSCC) have not yet been established.MethodsThe tumor proportion score (TPS), combined positive score (CPS), and soluble forms of programmed cell death ligand‐1 (PD‐L1) and programmed cell death ligand‐2 (PD‐L2) were retrospectively analyzed in patients with RMHNSCC treated with nivolumab.ResultsThe positivity rates for TPS (PD‐L1), CPS (PD‐L1), TPS (PD‐L2), and CPS (PD‐L2) were 73.8%, 78.2%, 56.4%, and 78.2%, respectively. Patients with high TPS (PD‐L1), CPS (PD‐L1), or CPS (PD‐L1 and PD‐L2) showed significantly prolonged progression‐free survival. Favorable overall survival was associated with high CPS (PD‐L1 and PD‐L2) and low soluble PD‐L1 and PD‐L2 levels. The expressions of tissue and soluble PD‐L1/2 were not correlated.ConclusionsOur study revealed that compared to PD‐L1 expression alone, dual expression of PD‐L1 and PD‐L2 in tissue or soluble form could be feasible biomarkers in patients with RMHNSCC who received nivolumab.

show abstract

“…Higher baseline sPD-L1 correlated with shorter OS after surgical resection in patients with gastric cancer [49,224], colorectal cancer [226,227], hepatocellular carcinoma [225], renal cell carcinoma [72], soft tissue sarcoma [229], and upper tract urothelial carcinoma [89]. Elevated sPD-L1 prior to surgery was also associated with worse disease-free survival (DFS) in patients with gastric cancer [49], colorectal cancer [226], head and neck cancer [228], and hepatocellular carcinoma [225] and with worse relapse-free survival in patients with gastric cancer [74] and colorectal cancer with liver metastasis [227]. Elevated pre-treatment sPD-L1 levels were also associated with lower metastasis-free survival (42.4% vs 88.4% rate at 5 years) following surgery in patients with soft tissue sarcoma [229].…”

Section: Spd-l1mentioning

confidence: 99%

Soluble immune checkpoints: implications for cancer prognosis and response to immune checkpoint therapy and conventional therapies

Pitts,

Schlom,

Donahue

2024

J Exp Clin Cancer Res

View full text Add to dashboard Cite

Longitudinal sampling of tumor tissue from patients with solid cancers, aside from melanoma and a few other cases, is often unfeasible, and thus may not capture the plasticity of interactions between the tumor and immune system under selective pressure of a given therapy. Peripheral blood analyses provide salient information about the human peripheral immunome while offering technical and practical advantages over traditional tumor biopsies, and should be utilized where possible alongside interrogation of the tumor. Some common blood-based biomarkers used to study the immune response include immune cell subsets, circulating tumor DNA, and protein analytes such as cytokines. With the recent explosion of immune checkpoint inhibitors (ICI) as a modality of treatment in multiple cancer types, soluble immune checkpoints have become a relevant area of investigation for peripheral immune-based biomarkers. However, the exact functions of soluble immune checkpoints and their roles in cancer for the most part remain unclear. This review discusses current literature on the production, function, and expression of nine soluble immune checkpoints – sPD-L1, sPD-1, sCTLA4, sCD80, sTIM3, sLAG3, sB7-H3, sBTLA, and sHVEM – in patients with solid tumors, and explores their role as biomarkers of response to ICI as well as to conventional therapies (chemotherapy, radiotherapy, targeted therapy, and surgery) in cancer patients.

show abstract

Prognostic and predictive role of soluble programmed death ligand-1 in head and neck cancer

Cited by 5 publications

References 25 publications

Soluble Programmed Death-Ligand 1 (sPD-L1) as a Promising Marker for Head and Neck Squamous Cell Carcinoma: Correlations With Clinical and Demographic Characteristics

Soluble Programmed Death-Ligand 1 (sPD-L1) as a Promising Marker for Head and Neck Squamous Cell Carcinoma: Correlations With Clinical and Demographic Characteristics

Combined approach for predicting the efficacy of nivolumab in head and neck carcinoma by tissue and soluble expressions of PD‐L1 and PD‐L2

Soluble immune checkpoints: implications for cancer prognosis and response to immune checkpoint therapy and conventional therapies

Contact Info

Product

Resources

About